Suchergebnisse

PubPharm (138)

11

WHO recommendation on advance misoprostol distribution to pregnant women for prevention of postpartum haemorrhage

Erschienen: Geneva, Switzerland, World Health Organization, [2020]

12

Treatment of chronic HCV with direct-acting antivirals

Erschienen: [Albany, N.Y.], New York State Department of Health AIDS Institute, June 2020

13

New Look to Phytomedicine : Advancements in Herbal Products as Novel Drug Leads

Erschienen: London, Academic Press, 2019

von Chattopadhyay, D. | Ahmad, I. | Khan, M.

14

Using central neuromodulators and psychological therapies to manage patients with disorders of gut-brain interaction : a clinical guide

Erschienen: Cham, Springer, [2019]

Springer eBooks, Medicine

von Sobin, W.

15

Pharmaceutical inhalation aerosol technology

Erschienen: Boca Raton, Florida, CRC Press,, [2019]

Drugs and the pharmaceutical sciences

Third edition.

von Hickey, A.

16

Nanocarriers for brain targeting : principles and applications

Erschienen: Toronto, Apple Academic Press,, 2019

von Keservani, R. | Sharma, A. | Kesharwani, R.

17

Clinical review report : (Novo nordisk Canada Inc.)Insulin degludec and liraglutide injection (Xultophy)

Erschienen: Ottawa (ON), CADTH, December 2019

CADTH common drug review

Version: final (with redactions).

18

Pharmacoeconomic review report : Insulin degludec and liraglutide injection (Xultophy) (Novo Nordisk Canada Inc.)

Erschienen: Ottawa (ON), CADTH, December 2019

CADTH common drug review

Version: Final (with redactions).

19

CADTH Canadian Drug Expert Committee recommendation : indication : adjunct to lifestyle modifications, for the once-daily treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycemic control in combination with metformin, with or without sulfonylurea, when these combined with basal insulin (less than 50 units daily) or liraglutide (less than or equal to 1.8 mg daily), do not provide adequate glycemic controlInsulin degludec and liraglutide (Xultophy -- Novo Nordisk Canada Inc.)

Erschienen: Ottawa (ON), CADTH, October 2019

CADTH common drug review

Version: 1.0.

20

Clinical review report : (ViiV Healthcare ULC)Dolutegravir/Lamivudine (Dovato)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, October 2019

CADTH common drug review

Version: Final (with redactions).